front-page.php

YURiA-PHARM is a Ukrainian pharmaceutical group of companies heading out into the world

90%

profits
reinvest

+20%

targets growth
annually

20+

new products
annually

600+

registration
certificates

41+

operate in countries
around the world

25%

is part of the
exports
Inscience Conference 2023
Growth

Inscience Conference 2023

On June 17-18, On June 17-18, Kyiv hosted a remarkable popular science event dedicated to science for the victory and reconstruction of Ukraine. Our R&D scientists of YURiA-PHARM had the opportunity to share their expertise in developing innovative mRNA-based vaccine solutions.  mRNA vaccines revolutionized medicine. Why, what makes them so special? And how can we…

Read more
Growth

We welcome Reka-Med to the YURіA-PHARM group of companies

Together, we will continue scaling up our activities in the countries of Central Asia. The role of Reka-Med is a production site that will meet the demand for YURіА-PHARM products in the countries of Central Asia, and in Ukraine. The company will implement the system and quality standards of YURіА-PHARM, which will make it possible…

Read more
War in Ukraine

Year of war in Ukraine

Last year for us, like all Ukrainians, was a daily test for stability and loyalty to a common idea. We each received a unique experience of restructuring processes and organizing work in new realities. From the very first days of the full-scale invasion, we began to resume manufacturing activities. Logistics is the most critical issue…

Read more
War in Ukraine

Test for resilience under energy deficiency

After massive missile strikes that destroyed critical infrastructure, we faced the need to reduce electricity consumption in order to save power in the unified energy system of Ukraine. At the same time, it was critically important for us to release the planned volume of products. We were preparing for different scenarios, the starting point for…

Read more

Key areas of R&D

  • Adaptation, development and scaling of technologies for the production of biopharmaceutical APIs and drugs based on them
  • Development of products based on hyaluronic acid
  • Development of Active Pharmaceutical Ingredients
  • Development and implementation in manufacturing of hospital drugs and medical devices
Find out more about R&D
Umerox<sup>®</sup> Ingal
For Partners
Products

Umerox® Ingal

Umerox® Ingal is an individual device designed for inhalation of methoxyflurane. Methoxyflurane, solution for inhalation, 2 ml administered through the Umerox® Ingal inhaler is a fast-acting, inhalable and non-narcotic analgesic. Indications for the use of Methoxyflurane are emergency relief of moderate to severe pain in adult patients with trauma who are conscious. Аnesthesia for short-term treatment…